Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia King Fahd ...

The protein expression of Ki-67, PCNA, pRb, p16, p53, Bcl-2 and Bax was evaluated by immunohistochemistry in archival tissue samples, collected from 15 patients with EAC and 5 patients with ...

An ELISA assay was utilized to analyze the levels of p53, Bcl-xL, NF-κB, and Bax. The results showed that the serum treatment not only reduced tumor volume but also reversed changes in p53, Bcl-xL, NF ...

ELISA assay was used to analyze the levels of p53, Bcl-xL, NF-κB, and Bax. The findings demonstrated that the serum treatment reduced tumor volume while also reversing changes in p53, Bcl-xL, NF-κB, ...

Analysis of isolated patient leukemic cells by FACS revealed induction of p53 targets Bax and Puma upon APR-246 treatment, and microarray analysis showed substantial alterations in gene expression, ...

Overexpression of ASPP1 potentiated, whereas knockdown of ASPP1 inhibited the expression of Bax (Bcl2-associated X), PUMA (p53 upregulated modulator of apoptosis), and Noxa, direct ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. The cell stress‐responsive transcription ...

phospho-p53, and Bax. On the contrary, PAQR3 inhibition played an opposite role in these proteins. Conclusion: PAQR3 inhibited the growth of NSCLC cells through the NF-κB/P53/Bax signaling pathway and ...

Expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma. Clin Exp Ophthalmol. 2015;43:259–267. 20 Appel ML, Edelweiss MI, Fleck J, et al. P53 and BCL-2 as ...

Investigators showed how p53 acts in the cytoplasm to trigger cell death by binding to and activating a protein called BAX. Using the tools of structural biology, researchers discovered the ...

and expression of p53 target genes including p21, Bax, BTG2, and MDM2. Daily intraperitoneal Nutlin-3a treatment for 3 weeks dose-dependently reduced PH, right ventricular hypertrophy, and distal ...